Research Center for Expert Evaluation of Objects of Medical Use

Moscow, Russia

Research Center for Expert Evaluation of Objects of Medical Use

Moscow, Russia

Time filter

Source Type

Sychev D.V.,Russian Academy of Medical Sciences | Ignatyev I.V.,Research Center for Expert Evaluation of Objects of Medical Use | Emelyanov N.V.,Research Center for Expert Evaluation of Objects of Medical Use | Milovanova V.V.,Research Center for Expert Evaluation of Objects of Medical Use | And 4 more authors.
Bulletin of Experimental Biology and Medicine | Year: 2012

The study included 52 patients at a high risk of thromboembolic complications, with permanent atrial fibrillation. All patients were treated with acenocoumarol for 6 months and the incidence of hemorrhages was evaluated in all of them. All patients were genotyped by CYP2C9 and VKORC1. The presence of CYP2C9*2 and CYP2C9*3 alleles of CYP2C9 locus and AA genotype of VCORC1 gene polymorphic G-1639(3673)A marker was not associated with the development of hemorrhages under conditions of acenocoumarol treatment (p=0.144 for CYP2C9, p=0.809 and 0.918 for VCORC1 in the total group and subgroup of patients with CYP2C9*1/*1 genotype, respectively). The search for other genetic markers of acenocoumarol efficiency and safety is needed for predicting the risk of hemorrhages during this treatment. © 2012 Springer Science+Business Media New York.

Loading Research Center for Expert Evaluation of Objects of Medical Use collaborators
Loading Research Center for Expert Evaluation of Objects of Medical Use collaborators